Answers are grounded in this paper and cite their sources.
Introduction Diabetes mellitus is a globally prevalent chronic metabolic disorder whose timely identification is critical to preventing irreversible end-organ damage. Although machine learning (ML) approaches have shown considerable promise for automated diabetes screening, the field is hampered by methodological deficiencies — notably data leakage during preprocessing and oversampler selection performed outside cross-validation folds — that collectively produce overoptimistic and clinically unreliable performance estimates. Methods We present a rigorously leakage-aware, multi-stage ML pipeline evaluated on a large-scale publicly available synthetic clinical dataset comprising 100,000 records and 15 features (prevalence 8.5%). The pipeline explicitly addresses two categories of leakage: (i) preprocessing leakage , by fitting all transformers exclusively on training data; and (ii) resampling leakage , by performing oversampler comparison entirely within cross-validation folds. The pipeline encompasses: (i) stratified three-way splitting into training, calibration, and held-out test partitions; (ii) an in-fold cross-validated comparison of seven resampling strategies against a no-resampling class-weighted baseline, with SMOTETomek selected automatically on cross-validated F1; (iii) training of four base classifiers (Logistic Regression, Random Forest, HistGradientBoosting, LightGBM); (iv) six model-fusion strategies; (v) isotonic probability calibration; (vi) decision curve analysis; and (vii) Mondrian class-conditional split-conformal prediction. Results Among all models, LightGBM, HistGradientBoosting, and the logarithmic pooling fusion ensemble (Fus-LogPool) achieved statistically equivalent top performance: PR-AUC of 0.8807 (Fus-LogPool), 0.8801 (LightGBM), and 0.8798 (HistGB), with pairwise McNemar tests uniformly non-significant ( p > 0.5), indicating that a simple well-tuned single gradient-boosted tree is as effective as fusion on this dataset. Mondrian conformal prediction attained 90.39% empirical coverage (target 90%), with 98.82% singleton predictions and singleton accuracy of 91.46%. Decision curve analysis confirmed net clinical benefit over treat-all and treat-none strategies across clinically relevant risk thresholds (5%–20%). SHAP global explanations identified HbA1c level, blood glucose level, BMI, and age as the dominant risk determinants. Discussion Importantly, all findings derive from a synthetic or semi-synthetic dataset without a verified clinical source, and must be validated on prospective real-world cohorts before any clinical application. The fully reproducible pipeline is released as an open-source Kaggle notebook.
No takes yet. Share an insight, caveat, or question.
Abrar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: